Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--is now no longer listed as being in short supply in the U.S. and the FDA has told anyone distributing copies of the ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention. Helen Coffey speaks to the dentists warning that jabs could have a worrying im ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

Mississippi Attorney General Lynn Fitch is warning Mississippians of unapproved and compounded weight loss drugs.

Every year, hundreds of celebrities grace the iconic steps of the Metropolitan Museum of Art in New York City to showcase ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

The Ohio Board of Pharmacy recently revoked the licenses of four Ohio medical spas, with concerns over the sourcing and ...